Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Stock Information for Gain Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gain Therapeutics Inc.

Gain Therapeutics to Present at the 38th Annual ROTH Conference
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.